Understand the source comparison
Peptides Help Carpal Tunnel: Research vs Clinical Use
Mechanism VEGF upregulation, angiogenesis promotion Actin regulation, cell migration enhancement Anti-inflammatory (COX-2 inhibition) Physical release of median nerve Onset of Effect 2–4 weeks 3–6 weeks 24–72 hours Immediate post-op Evidence Level Preclinical
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism
- VEGF upregulation, angiogenesis promotion
- Actin regulation, cell migration enhancement
- Anti-inflammatory (COX-2 inhibition)
- Physical release of median nerve
- Onset of Effect
- 2–4 weeks
- 3–6 weeks
- 24–72 hours
- Immediate post-op
- Evidence Level
- Preclinical (animal models)
- Phase 3 clinical trials
- Gold standard (surgical literature)
- Regulatory Status
- Research use only
- FDA-approved
- Covered procedure
- Fibrosis Risk
- Reduces fibrotic tissue formation
- Reduces scar tissue density
- Neutral (symptom management)
- Can trigger adhesion formation
- Professional Assessment
- Promising for early-stage intervention; no human RCT data
- Strong regenerative signal in nerve injury models
- Temporary symptom relief; does not reverse compression
- Necessary when structural damage is advanced